Merck KGaA in Focus of Analysts
There is currently no specific information that Deutsche Bank Research has rated Merck KGaA with a “Buy” rating and a price target of 174 euros. However, there are reports that DZ Bank has given Merck KGaA a “Buy” rating with an average price target of 171.06 euros.
Short Portrait of Merck KGaA
Merck KGaA is a leading company in the field of pharmaceuticals and chemicals, operating in three main areas:
- Research and Biotechnology: Solutions and products for scientific and biotechnological research account for about 42.1% of net sales.
- Pharmaceutical Products: This includes prescription medications for the treatment of various diseases and contributes about 40% to net sales.
- Performance Materials: Products for the electronics industry include semiconductor materials and liquid crystals, which account for about 17.9% of net sales.
Additionally, there are reports of a potential acquisition of SpringWorks Therapeutics by Merck KGaA, which would be considered one of the largest pharma deals of the company.
Importance of Analyst Ratings
The evaluation of Merck KGaA by analysts is crucial for investors in the pharmaceutical sector as it provides valuable insights into the company’s potential. Analysts like Falko Friedrichs may give positive forecasts for Merck KGaA, likely due to strategic decisions and strong market position.
However, it is advisable to check the exact details of the evaluation by Deutsche Bank, as current information may not be available.